HIGHLIGHTS
- who: Report and collaborators from the Internal Medicine, University at Buffalo, Buffalo, USA Pathology, University at Buffalo, Buffalo, USA, . have published the Article: Review began 02/21/2023 Review ended 03/02/2023 Published 03/07/2023 u00a9 Copyright, in the Journal: (JOURNAL) of March/07,/2023
- what: The trial showed median overall survival of 11.7 months in the gemcitabine-cisplatin (gem-cis) group compared to 8.1 months in the gemcitabineonly group.
SUMMARY
Cholangiocarcinoma (CCA) is a biliary tumor comprising 15% of all primary liver tumors and 3% of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.